A CD4+ T lymphocyte-specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Gasdermin (GSDM) proteins are known to mediate pyroptosis and influence cancer progression.
• The role of GSDM proteins in the tumor immune microenvironment is largely unexplored.

Purpose of the Study:

• To investigate the function of Gasdermin D (GSDMD) in the tumor immune microenvironment.
• To elucidate the non-pyroptotic roles of GSDMD in anti-tumor immunity.

Main Methods:

• Analysis of GSDMD activation in human tumor specimens.
• GSDMD deficiency and inactivation studies in CD4+ T cells using mouse models.
• Investigation of IL-2 production and T cell help mechanisms.
• Biochemical assays to study GSDMD pore formation and calcium influx.

Main Results:

• GSDMD activation in human tumors primarily occurs in tumor-infiltrating leukocytes.
• GSDMD deficiency in CD4+ T cells impairs CD8+ T cell-mediated anti-tumor immunity and promotes tumor growth.
• GSDMD is essential for CD4+ T cell-mediated help to CD8+ T cells via IL-2 induction.
• GSDMD-N pore formation enhances Ca2+ influx, leading to IL-2 production upon T cell receptor stimulation.
• GSDMD function is conserved in human CD4+ T cells and correlates with better prognosis and immunotherapy response.

Conclusions:

• GSDMD plays a critical non-pyroptotic role in orchestrating CD4+ T cell help for CD8+ T cell anti-tumor immunity.
• GSDMD activation is a potential biomarker for immunotherapy response.
• GSDMD represents a novel therapeutic target for enhancing cancer immunotherapy.